Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth

CONCLUSIONS: This study highlights the synergistic immunomodulatory effects of REG and aPD1 combination therapy in mediating a sustained inhibition of colon cancer regrowth, strongly warranting clinical evaluation in CRC, including MSS tumors.PMID:34517894 | DOI:10.1186/s13046-021-02043-0

Source: Clinical Colorectal Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Dennis Doleschel Sabine Hoff Susanne Koletnik Anne Rix Dieter Zopf Fabian Kiessling Wiltrud Lederle Source Type: research